1 |
Zheng R, Wang S, Zhang S, et al.Global, regional, and national lifetime probabilities of developing cancer in 2020[J].Sci Bull(Beijing), 2023,68(21):2620-2628.
|
2 |
Shin AE, Giancotti FG, Rustgi AK.Metastatic colorectal cancer:mechanisms and emerging therapeutics[J].Trends Pharmacol Sci,2023, 44(4):222-236.
|
3 |
Siegel RL, Wagle NS, Cercek A, et al.Colorectal cancer statistics,2023[J].CA Cancer J Clin, 2023, 73(3):233-254.
|
4 |
Ren H, Song Z, Chao C, et al.circCCDC66 promotes thyroid cancer cell proliferation,migratory and invasive abilities and glycolysis through the miR-211-5p/PDK4 axis[J].Oncol Lett, 2021, 21(5):416.doi: 10.3892/ol.2021.12677.
|
5 |
Yang R, Wang Z, Meng G, et al.Circular RNA CCDC66 facilitates abdominal aortic aneurysm through the overexpression of CCDC66[J].Cell Biochem Funct, 2020, 38(7):830-838.
|
6 |
Nemeth K, Bayraktar R, Ferracin M, et al.Non-coding RNAs in disease:from mechanisms to therapeutics[J].Nat Rev Genet, 2024,25(3):211-232.
|
7 |
Ivanovic RF, Viana NI, Morais DR, et al.miR-618:possible control over TIMP-1 and its expression in localized prostate cancer[J].BMC Cancer, 2018, 18(1):992.doi:10.1186/s12885-018-4930-4.
|
8 |
Batea HM, El-Dine SHM, Kamha EM, et al.The predictive value of hsa_circ_0001313 (circCCDC66) in Egyptian rectal cancer patients:a new era in precision medicine[J].JCP, 2024, 44(3): e163-e170.
|
9 |
Jacobsson M, Wagner V, Kanneganti S.Screening for colorectal cancer[J].Surg Clin North Am, 2024, 104(3):595-607.
|
10 |
Hsiao KY, Lin YC, Gupta SK, et al.Noncoding effects of circular RNA CCDC66 promote colon cancer growth and metastasis[J].Cancer Res,2017, 77(9):2339-2350.
|
11 |
GBD 2019 Colorectal Cancer Collaborators.Global, regional, and national burden of colorectal cancer and its risk factors,1990-2019:a systematic analysis for the Global Burden of Disease Study 2019[J].Lancet Gastroenterol Hepatol, 2022, 7(7):627-647.
|
12 |
黄忠晶, 伍子奕, 艾军华.肝移植治疗结直肠癌肝转移的研究进展[J].器官移植, 2024, 15 (2): 185-190.
|
13 |
Ionescu VA, Gheorghe G, Bacalbasa N, et al.Colorectal cancer: from risk factors to oncogenesis[J].Medicina (Kaunas), 2023, 59(9):1646.doi: 10.3390/medicina59091646.
|
14 |
Abedizadeh R, Majidi F, Khorasani HR, et al.Colorectal cancer: a comprehensive review of carcinogenesis,diagnosis, and novel strategies for classified treatments[J].Cancer Metastasis Rev, 2024, 43(2):729-753.
|
15 |
Benson AB, Venook AP, Al-Hawary MM, et al.Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology[J].J Natl Compr Canc Netw, 2021, 19(3):329-359.doi:10.6004/jnccn.2021.0012.
|
16 |
Hsiao KY, Lin YC, Gupta SK, et al.Noncoding effects of circular RNA CCDC66 promote colon cancer growth and metastasis[J].Cancer Res,2017, 77(9):2339-2350.
|
17 |
Radanova M, Mihaylova G, Mihaylova Z, et al.Circulating miR- 618 has prognostic significance in patients with metastatic colon cancer[J].Curr Oncol, 2021, 28(2):1204-1215.
|
18 |
Chen Z, Chen W, Hong Z, et al.MiR-618 suppresses the proliferation,invasion, and migration of non-small lung cancer via the JAK2/STAT3 axis[J].J Cardiothorac Surg, 2024, 19(1):679.doi:10.1186/s13019-024-03160-5.
|
19 |
Song XL, Tang Y, Lei XH, et al.miR-618 inhibits prostate cancer migration and invasion by targeting FOXP2[J].J Cancer, 2017,8(13):2501-2510.doi:10.7150/jca.17407.
|
20 |
Hashemi M, Etemad S, Rezaei S, et al.Progress in targeting PTEN/PI3K/Akt axis in glioblastoma therapy:Revisiting molecular interactions[J].Biomed Pharmacother, 2023, 158:114204.doi: 10.1016/j.biopha.2022.114204.
|
21 |
Bergholz JS, Wang Q, Wang Q, et al.PI3Kβ controls immune evasion in PTEN-deficient breast tumours[J].Nature, 2023, 617(7959):139-146.
|
22 |
Christine A, Park MK, Song SJ, et al.The equilibrium of tumor suppression: DUBs as active regulators of PTEN[J].Exp Mol Med,2022, 54(11):1814-1821.
|
23 |
Tu T, Chen J, Chen L, et al.Dual-specific protein and lipid phosphatase PTEN and its biological functions[J].Cold Spring Harb Perspect Med,2020, 10(1):a036301.doi:10.1101/cshperspect.a036301.
|
24 |
Morana O, Wood W, Gregory CD.The apoptosis paradox in cancer[J].Int J Mol Sci, 2022, 23(3):1328.doi: 10.3390/ijms23031328.
|
25 |
He Y, Sun MM, Zhang GG, et al.Targeting PI3K/Akt signal transduction for cancer therapy[J].Sig Transduct Target Ther, 2021,6(1):425.doi: 10.1038/s41392-021-00828-5.
|
26 |
Meng X, Cui J, He G.Bcl-2 is involved in cardiac hypertrophy through PI3K-Akt pathway[J].Biomed Res Int, 2021, 2021:6615502.doi:10.1155/2021/6615502.
|
27 |
Kaloni D, Diepstraten ST, Strasser A, et al.BCL-2 protein family:attractive targets for cancer therapy[J].Apoptosis, 2023, 28(1-2):20-38.
|
28 |
Wan L, Wang Y, Li J, et al.Inhibition of the AKT/mTOR pathway negatively regulates PTEN expression via miRNAs[J].Acta Biochim Biophys Sin (Shanghai), 2022, 54(11):1637-1647.
|
29 |
You J, Wu Q, Li Y, et al.Lentinan induces apoptosis of mouse hepatocellular carcinoma cells through the EGR1/PTEN/AKT signaling axis[J].Oncol Rep, 2023, 50(1):142.doi: 10.3892/or.2023.8579.
|